Company Description
Immunome, Inc., a biotechnology company, engages in the discovery, design, development, manufacturing, and commercialization of antibody-drug conjugates and other oncology therapeutics in the United States.
The company develops clinical asset comprising Varegacestat, a gamma secretase inhibitor that is in Phase 3 clinical trial for the treatment of desmoid tumors; and IM-1021, a receptor tyrosine kinase-like orphan receptor 1 antibody-drug conjugate (ADC), which is in Phase 1 clinical trial.
It is also developing preclinical assets, including IM-3050, a fibroblast activation protein targeted radioligand therapy; and solid tumor ADC drug candidates, such as IM-1617, IM-1340, and IM-1335.
Immunome, Inc. was incorporated in 2006 and is based in Bothell, Washington.
| Country | United States |
| Founded | 2006 |
| IPO Date | Oct 2, 2020 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 177 |
| CEO | Clay Siegall |
Contact Details
Address: 18702 North Creek Parkway, Suite 100 Bothell, Washington 98011 United States | |
| Phone | 425 939 7410 |
| Website | immunome.com |
Stock Details
| Ticker Symbol | IMNM |
| Exchange | NASDAQ |
| Stock Type | Common Stock |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| IPO Price | $12.00 |
| CIK Code | 0001472012 |
| CUSIP Number | 45257U108 |
| ISIN Number | US45257U1088 |
| Employer ID | 77-0694340 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Dr. Clay B. Siegall Ph.D. | Chairman, President and Chief Executive Officer |
| Sandra G. Stoneman Esq., J.D. | Chief Legal Officer, General Counsel and Corporate Secretary |
| Kinney Horn | Chief Business Officer |
| Max Rosett | Chief Financial Officer |
| Dr. Philip Tsai | Chief Technical Officer |
| Dr. Jack Higgins Ph.D. | Chief Scientific Officer |
| Dr. Robert J. Lechleider M.D. | Chief Medical Officer |
| Roee Shahar | Executive Vice President of Commercial |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Apr 24, 2026 | ARS | Filing |
| Apr 24, 2026 | DEFA14A | Additional definitive proxy soliciting materials and Rule 14(a)(12) material |
| Apr 24, 2026 | DEF 14A | Other definitive proxy statements |
| Apr 3, 2026 | 144/A | Filing |
| Apr 2, 2026 | 144 | Filing |
| Apr 2, 2026 | 144 | Filing |
| Mar 26, 2026 | SCHEDULE 13G/A | Filing |
| Mar 20, 2026 | 144 | Filing |
| Mar 3, 2026 | S-8 | Securities to be offered to employees in employee benefit plans |
| Mar 3, 2026 | 10-K | Annual Report |